|
May 19, 2020
|
Oyster Point Pharma Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
PRINCETON, N.J., May 19, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced the closing of a public
|
|
|
May 15, 2020
|
Oyster Point Pharma Announces Pricing of an Upsized Offering of Common Stock
PRINCETON, N.J., May 15, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced the pricing of its
|
|
|
May 12, 2020
|
Oyster Point Pharma Proposed Public Offering of Common Stock
PRINCETON, N.J., May 12, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that it has commenced an
|
|
|
May 11, 2020
|
Oyster Point Pharma Announces Positive Results in ONSET-2 Phase 3 Trial of OC-01 Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease
ONSET-2 met the prespecified primary endpoint in both doses tested, demonstrating statistically significant improvement in Schirmer’s score from baseline to Week 4 in subjects receiving OC-01 nasal spray versus control (p
|
|
|
May 11, 2020
|
Oyster Point Pharma Reports First Quarter 2020 Financial Results and Recent Business Highlights
Announces Positive Results in ONSET-2 Phase 3 Trial of OC-01 Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease ONSET-2 Data Enables NDA Submission in 2H 2020 Cash and Cash Equivalents of $128.6 million as of March 31, 2020 Conference Call and Webcast Scheduled for 8:00 am
|
|
|
May 04, 2020
|
Oyster Point Pharma to Report First Quarter 2020 Financial Results on May 11, 2020
Conference Call and Webcast Scheduled for May 11, 2020, 8:00 am ET PRINCETON, N.J., May 04, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical
|
|
|
Mar 30, 2020
|
Oyster Point Pharma Completes Enrollment in ONSET-2 Pivotal Phase 3 Clinical Trial of OC-01 Nasal Spray for Dry Eye Disease and Provides COVID-19 Business Update
ONSET-2 Phase 3 Top-Line Data Expected by End of Q2 2020 NDA Submission Expected During 2H 2020 PRINCETON, N.J., March 30, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and
|
|
|
Feb 27, 2020
|
Oyster Point Pharma Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights
ONSET-2 Phase 3 Top-Line Data Expected by End of Q2 2020 Cash and Cash Equivalents of $139.1 million as of December 31, 2019 Conference Call and Webcast Scheduled for 4:30 pm ET PRINCETON, N.J., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc.
|
|
|
Feb 24, 2020
|
Oyster Point Pharma to Report Fourth Quarter and Full Year 2019 Financial Results on February 27, 2020
Conference Call and Webcast Scheduled for February 27, 2020, 4:30 pm ET PRINCETON, N.J., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class
|
|
|
Feb 24, 2020
|
Oyster Point Pharma to Present at the Cowen 40th Annual Healthcare Conference
PRINCETON, N.J., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, announced that Jeffrey
|
|
